IMU is a discovery engine mapping the immune system to advance precision medicine.
IMU is a discovery engine mapping the immune system to advance precision medicine.
What they do: Multi-omic, high-resolution immune-profiling platform (CytAtlas / IMU) with AI analytics for precision medicine
Founded: 2021
Headquarters / Industry: London / Biotechnology Research
Recent funding: Series A announced Jan 24, 2024 (led by Molten Ventures)
Decoding the human immune system to enable precision medicine applications (diagnostics, monitoring, drug discovery and treatment-response prediction).
2021
Biotechnology Research
£11.5M
Announced close of Series A financing; reported as £11.5M
Earlier venture round listed with Beaumont Capital
“Led by Molten Ventures in Series A; earlier investor participation includes Beaumont Capital and Life Extension Ventures”
| Company |
|---|
 |
 |
 |
 |
 |